Rhumbline Advisers Grows Stake in Sarepta Therapeutics Inc (SRPT)

Rhumbline Advisers grew its holdings in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 18.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 72,543 shares of the biotechnology company’s stock after purchasing an additional 11,081 shares during the quarter. Rhumbline Advisers owned approximately 0.11% of Sarepta Therapeutics worth $3,291,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SRPT. Ameritas Investment Partners Inc. increased its holdings in Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 271 shares in the last quarter. Advisor Group Inc. increased its holdings in Sarepta Therapeutics by 3.2% in the 2nd quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock worth $351,000 after acquiring an additional 326 shares in the last quarter. Legal & General Group Plc increased its holdings in Sarepta Therapeutics by 3.9% in the 2nd quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock worth $593,000 after acquiring an additional 663 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in Sarepta Therapeutics by 0.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock worth $3,703,000 after acquiring an additional 818 shares in the last quarter. Finally, C WorldWide Group Holding A S increased its holdings in Sarepta Therapeutics by 0.8% in the 3rd quarter. C WorldWide Group Holding A S now owns 122,469 shares of the biotechnology company’s stock worth $5,555,000 after acquiring an additional 941 shares in the last quarter. 82.02% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts recently issued reports on the stock. Credit Suisse Group reissued an “outperform” rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Robert W. Baird restated a “buy” rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. Piper Jaffray Companies restated an “overweight” rating and issued a $55.00 price target (up from $50.00) on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. Finally, J P Morgan Chase & Co restated a “hold” rating on shares of Sarepta Therapeutics in a research note on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $64.14.

Shares of Sarepta Therapeutics Inc (SRPT) opened at $53.72 on Friday. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics Inc has a 52 week low of $26.26 and a 52 week high of $57.57.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. The business had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. During the same quarter last year, the firm posted ($0.95) earnings per share. equities research analysts anticipate that Sarepta Therapeutics Inc will post -3.11 EPS for the current year.

In other news, SVP Shamim Ruff sold 10,000 shares of the firm’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $55.00, for a total transaction of $550,000.00. Following the transaction, the senior vice president now owns 37,045 shares in the company, valued at $2,037,475. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the firm’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the transaction, the director now owns 13,333 shares in the company, valued at approximately $745,181.37. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,167 shares of company stock worth $1,497,619. Insiders own 9.60% of the company’s stock.

WARNING: This story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2017/12/08/rhumbline-advisers-grows-stake-in-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply